PD

Peter Dubec

Director Of Product Engineering at MindMed

Peter Dubec has a diverse work experience in various companies and roles. Peter is currently working at MindMed as the Director of Product Engineering, leading a team in the development of AI-based biotech and healthcare software products in the field of psychedelic-inspired medicines and therapies. Peter is involved in regulatory interactions and clinical studies for the development of Software as a Medical Device.

Prior to their current role, Peter worked as a Product Engineering Lead at MindMed and as a Senior Product Engineer at HealthMode, where they played a key role in building the company's first product prototypes and scaling up the engineering team. HealthMode was later acquired after raising significant funding.

Before their time at HealthMode, Peter worked as a Product Engineer at CEAI, Inc, focusing on web application development in the field of financial crime detection. Peter utilized the latest frontend technologies to enhance user experience and solve challenges related to data visualization and management.

Peter also gained experience as a Junior Frontend Developer at Shortlist and as the Founder & Project Manager at TeeVee, a successful online content streaming platform. In addition, they worked as a Partner & Redactor at Svet IT.

Overall, Peter Dubec has a strong background in product engineering, with expertise in software development, regulatory compliance, and team leadership.

Peter Dubec earned a Bachelor's Degree in Informatics from the Slovak University of Technology in Bratislava, Faculty of Informatics and Information Technologies in 2015. Peter then went on to pursue a Master's Degree in Information Systems from the same institution, completing it in 2017. Prior to their university studies, Peter attended Gymnázium Nováky where they completed their high school education with a focus on foreign languages.

Links

Timeline

  • Director Of Product Engineering

    April, 2022 - present

  • Product Engineering Lead

    April, 2021

View in org chart